We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
151
Inogen
INGN
$174M
$5K ﹤0.01%
+125
New +$5.29K
DCOY
152
Decoy Therapeutics
DCOY
$2.14M
– –
0
– –
ADUS icon
153
Addus HomeCare
ADUS
$2.22B
– –
-7,601
Closed -$237K
BCLI
154
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-26,667
Closed -$916K
BCRX icon
155
BioCryst Pharmaceuticals
BCRX
$2.42B
– –
-123,745
Closed -$1.41M
BHC icon
156
CALL
Bausch Health
BHC
$1.75B
– –
-100
Closed -$18K
CAH icon
157
Cardinal Health
CAH
$53.7B
– –
-2,574
Closed -$198K
ELV icon
158
Elevance Health
ELV
$81.5B
– –
-1,436
Closed -$201K
EW icon
159
Edwards Lifesciences
EW
$49.4B
– –
-9,000
Closed -$213K
GILD icon
160
PUT
Gilead Sciences
GILD
$165B
– –
-100,000
Closed -$9.82M
HCA icon
161
HCA Healthcare
HCA
$90.6B
– –
-2,563
Closed -$198K
IRWD icon
162
Ironwood Pharmaceuticals
IRWD
$586M
– –
-102,957
Closed -$899K
IWM icon
163
PUT
iShares Russell 2000 ETF
IWM
$79.1B
– –
-200,000
Closed -$21.8M
NVO
164
PUT
Novo Nordisk
NVO
$228B
– –
-400,000
Closed -$10.8M
PTCT icon
165
CALL
PTC Therapeutics
PTCT
$6.18B
– –
-100,000
Closed -$2.67M
PTCT icon
166
PUT
PTC Therapeutics
PTCT
$6.18B
– –
-1,005,000
Closed -$26.8M
RGEN icon
167
PUT
Repligen
RGEN
$6.91B
– –
-100,000
Closed -$2.79M
SSO icon
168
PUT
ProShares Ultra S&P500
SSO
$7.52B
– –
-1,600,000
Closed -$11.1M
TBT icon
169
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$300M
– –
-12,000
Closed -$520K
UUP icon
170
Invesco DB US Dollar Index Bullish Fund
UUP
$423M
– –
-55,000
Closed -$1.38M
XBI icon
171
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-100
Closed -$6K
XBI icon
172
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-275,000
Closed -$17.1M
XNCR icon
173
PUT
Xencor
XNCR
$1.45B
– –
-50,000
Closed -$612K
VIRX
174
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-3,333
Closed -$567K
SCTL
175
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-13,450
Closed -$145K
4 5 6
7
8

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.